Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06434103CT.gov Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC | — | Withdrawn | — | — | — |
NCT06480136CT.gov SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment | — | Not Yet Recruiting | — | — | — |
NCT06465238CT.gov Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Shr-A1921 (this asset) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P2 | CCC · 50 |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Endostatin | Henan Cancer Hospital | P4 | BBB |
| Zorifertinib | Alpha Biopharma (Jiangsu) Co., Ltd. | P2/3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Vinorelbine Ditartrate | Intergroupe Francophone de Cancerologie Thoracique | P4 | BB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Shr-A1921
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Cancer | — | P3 | CCC · 54 |
| Metastatic Malignant Neoplasm In The Brain | — | P2 | CCC · 51 |
| Hormone Receptor-Positive Breast Cancer | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Shr-A1921 in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/shr-a1921-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →